{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=60", "query": { "condition": "Hematologic", "page": 60 }, "page_size": 10 }, "pagination": { "page": 60, "page_size": 10, "total_count": 10741, "total_pages": 1075, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=61&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=59&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:48:27.853Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02659293", "title": "Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide (Control)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2016-04-26", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 2, "location_summary": "Chicago, Illinois • Detroit, Michigan", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02659293" }, { "nct_id": "NCT00946647", "title": "A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Panobinostat (LBH589)", "type": "DRUG" }, { "name": "5-Azacytidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2009-12-02", "completion_date": "2019-04-29", "has_results": true, "last_update_posted_date": "2020-08-04", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 8, "location_summary": "Augusta, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 5 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00946647" }, { "nct_id": "NCT00548847", "title": "Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "Interferon-α-2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 15, "start_date": "2007-01", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-10-26", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00548847" }, { "nct_id": "NCT04095858", "title": "Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hematopoietic Stem Cell Transplantation", "Acute Graft Versus Host Disease", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Efprezimod alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-01-05", "completion_date": "2021-11-05", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 4, "location_summary": "Duarte, California • Chicago, Illinois • Hershey, Pennsylvania + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04095858" }, { "nct_id": "NCT05283148", "title": "Sickle Cell Disease (SCD) Bone Pain Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sickle Cell Disease", "Sickle Cell Anemia", "Low Bone Density", "Osteoporosis", "Osteopenia", "Vertebral Fracture", "Vertebral Compression", "Osteonecrosis", "Ischemic Necrosis", "Avascular Necrosis" ], "interventions": [ { "name": "Dual-energy X-ray absorptiometry", "type": "OTHER" }, { "name": "Vertebral fracture analysis", "type": "OTHER" }, { "name": "Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 53, "start_date": "2022-11-03", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283148" }, { "nct_id": "NCT00006055", "title": "Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Purpura, Schoenlein-Henoch", "Graft Versus Host Disease", "Anemia, Hemolytic, Autoimmune", "Rheumatoid Arthritis", "Churg-Strauss Syndrome", "Hypersensitivity Vasculitis", "Wegener's Granulomatosis", "Systemic Lupus Erythematosus", "Giant Cell Arteritis", "Pure Red Cell Aplasia", "Juvenile Rheumatoid Arthritis", "Polyarteritis Nodosa", "Autoimmune Thrombocytopenic Purpura", "Takayasu Arteritis" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "Autologous Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fairview University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "55 Years", "sex": "ALL", "summary": "1 Year to 55 Years" }, "enrollment_count": 10, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006055" }, { "nct_id": "NCT01484015", "title": "Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia", "Adult Acute Myeloid Leukemia", "Adult Burkitt Lymphoma", "Adult Diffuse Large Cell Lymphoma", "Adult Diffuse Mixed Cell Lymphoma", "Adult Diffuse Small Cleaved Cell Lymphoma", "Adult Hodgkin Lymphoma", "Adult Immunoblastic Large Cell Lymphoma", "Adult Lymphoblastic Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Breast Cancer", "Chronic Eosinophilic Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cutaneous T-cell Non-Hodgkin Lymphoma", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3 Follicular Lymphoma", "Malignant Testicular Germ Cell Tumor", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Multiple Myeloma", "Mycosis Fungoides/Sezary Syndrome", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neutropenia", "Nodal Marginal Zone B-cell Lymphoma", "Ovarian Epithelial Cancer", "Ovarian Germ Cell Tumor", "Plasma Cell Neoplasm", "Poor Prognosis Metastatic Gestational Trophoblastic Tumor", "Primary Myelofibrosis", "Prolymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "cefepime hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484015" }, { "nct_id": "NCT00020371", "title": "BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific", "Neutropenia" ], "interventions": [ { "name": "BMS-247550", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020371" }, { "nct_id": "NCT00961064", "title": "A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Thrombocytopenia" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 30, "start_date": "2011-03-15", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00961064" }, { "nct_id": "NCT04543409", "title": "A Study of Benralizumab in Patients With Eosinophilic Esophagitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Matching placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 211, "start_date": "2020-09-22", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-15T11:48:27.853Z", "location_count": 22, "location_summary": "Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 17 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Normal", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04543409" } ] }